Pancreatic Adenocarcinoma

Stage anatomy before choosing a needle or operation

Diagnosis and resectability are linked, but tissue timing depends on the intended treatment path.

Obtain high-quality multiphase pancreas-protocol CT of the chest, abdomen, and pelvis to define the primary tumor, liver and peritoneal spread, nodes, and its interface with the celiac axis, superior mesenteric artery, common hepatic artery, portal vein, and superior mesenteric vein.

MRI can clarify indeterminate liver or pancreatic findings, while EUS detects small lesions and provides tissue. When tissue is needed, current ASGE guidance favors EUS-guided fine-needle biopsy over fine-needle aspiration for a solid pancreatic mass.

Histologic confirmation is required before neoadjuvant therapy, chemotherapy, or treatment of unresectable disease. A classic clearly resectable mass may proceed to surgery without preoperative biopsy after multidisciplinary review when no alternative diagnosis is likely.

Relieve biliary obstruction when cholangitis, severe symptoms, organ dysfunction, or treatment delay makes drainage necessary; do not let a stent substitute for complete staging.

Head and tail tumors tell different stories

Location controls which structure is obstructed first and how early the cancer becomes visible.

Pancreatic ductal adenocarcinoma is the dominant exocrine pancreatic malignancy and most often arises in the head, where even a smaller lesion can obstruct the distal common bile duct.

Head tumors commonly produce painless jaundice, pruritus, dark urine, pale stools, cholestatic liver tests, and sometimes a palpable nontender gallbladder called Courvoisier sign.

Body and tail tumors are farther from the bile duct and often present later with deep epigastric or back pain, weight loss, new or worsening diabetes, venous thromboembolism, or metastatic disease.

Jaundice localizes toward the head; its absence does not lower the danger of a body or tail lesion.

CA 19-9 is an adjunct, not a verdict

The marker becomes useful only after anatomy and clinical context are known.

CA 19-9 has insufficient sensitivity and specificity for population screening or stand-alone diagnosis. Cholestasis, cholangitis, and other benign conditions can elevate it.

Some patients do not express the Lewis antigen and may have little or no CA 19-9 production even with advanced cancer, so a normal value never excludes pancreatic adenocarcinoma.

After biliary obstruction is relieved when feasible, a baseline and serial CA 19-9 can complement imaging and clinical assessment of treatment response or recurrence, but treatment should not be changed on one marker value alone.

CA 19-9 follows the case; it does not make the case.

Vessels define resectability

A small tumor wrapped around a critical artery can be less operable than a larger tumor clear of the mesenteric axis.

Resectability depends on absence of distant metastasis and the degree and reconstructibility of tumor contact with the superior mesenteric and portal veins and the superior mesenteric, celiac, and common hepatic arteries.

Pancreatic head tumors are treated with pancreaticoduodenectomy when resectable, while body or tail tumors generally require distal pancreatectomy, often with splenectomy.

Borderline resectable disease has vascular involvement that may become operable after neoadjuvant therapy; locally advanced disease has unreconstructible or extensive vascular involvement without distant metastasis and usually begins with systemic therapy.

Risk and paraneoplastic clues change suspicion

No single risk factor diagnoses cancer, but some presentations should move pancreatic imaging to the front.

Risk rises with age, cigarette smoking, obesity, chronic pancreatitis, long-standing or new-onset diabetes, family history, and inherited syndromes involving genes such as BRCA1, BRCA2, PALB2, ATM, CDKN2A, STK11, and mismatch repair pathways.

Trousseau syndrome describes migratory superficial thrombophlebitis or recurrent venous thromboembolism driven by a hypercoagulable malignancy, classically including pancreatic adenocarcinoma.

New diabetes plus weight loss, recurrent idiopathic pancreatitis in an older adult, or unexplained thrombosis should trigger attention to an occult pancreatic tumor rather than automatic attribution to common disease.

Migrating clot plus weight loss can be the cancer speaking before the pancreas does.

Treatment follows resectability, biology, and fitness

Surgery and systemic therapy are partners in localized disease; advanced disease still needs precise selection and palliation.

Resectable disease requires multidisciplinary review. Many patients proceed to resection followed by adjuvant chemotherapy, with modified FOLFIRINOX favored for fit patients and other gemcitabine- or fluoropyrimidine-based options selected by fitness and contraindications; selected high-risk resectable tumors may receive neoadjuvant therapy.

Borderline resectable disease generally receives neoadjuvant multiagent systemic therapy, sometimes with radiation in selected programs, followed by restaging and surgery only when a margin-negative resection appears achievable.

Locally advanced unresectable disease begins with systemic therapy and supportive care, with repeat assessment for rare conversion to resection and selective radiation for local control.

Metastatic disease is treated with systemic therapy matched to performance status and comorbidity. Fit patients may receive FOLFIRINOX, NALIRIFOX, or gemcitabine plus nab-paclitaxel; frailer patients need attenuated therapy or symptom-focused care.

Offer appropriate germline testing and tumor molecular profiling because uncommon findings can direct platinum sensitivity, PARP maintenance, immune checkpoint therapy, or rare targeted treatments. Integrate biliary drainage, analgesia, celiac plexus intervention, PERT, nutrition, thrombosis care, and early palliative care as needed.